Akebia Therapeutics (AKBA) Price & Analysis

Compare

1,555 Followers

AKBA Stock Chart & Stats

$1.59

$0.30(14.49%)

At close: Jan 21 4:00 PM EST

$1.59

$0.30(14.49%)

Day’s Range― - ―

52-Week Range$1.52 - $4.08

Previous CloseN/A

Volume5.66M

Average Volume (3M)5.19M

Market Cap

$467.04M

Enterprise Value$794.19M

Total Cash (Recent Filing)$166.44M

Total Debt (Recent Filing)$52.58M

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Mar 12, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding265,366,000

10 Day Avg. Volume6,713,648

30 Day Avg. Volume5,192,429

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)-8.15

Price to Sales (P/S)2.50

P/FCF Ratio-9.85

Enterprise Value/Market Cap1.70

Enterprise Value/Revenue3.53

Enterprise Value/Gross Profit4.48

Enterprise Value/Ebitda37.41

Forecast

1Y Price Target

$6.00

Price Target Upside277.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)0.05

Revenue Forecast (FY)$242.69M

Bulls Say, Bears Say

Bulls Say

Clinical OutcomesThe presentation showed meaningful and greater favorable outcomes in the composite all-cause mortality and hospitalization for vadadustat compared to the ESA control.

Market ExpansionWith the addition of DaVita's patient base, management expects prescribing access to Vafseo to increase by more than four times by YE25 from 3Q25, and by more than seven times at the start of 2026 compared to the start of 2025.

Regulatory DesignationThe CMS has granted TDAPA designation for Vafseo, making it eligible to receive additional reimbursement on top of the ESRD bundled rate for a two-year period that started in January 2025.

Bears Say

Growth SaturationVafseo revenues fell below expectations as growth moderated, likely reflecting saturation of the current patient addressable base.

Missed Market OpportunityThe removal of the CKD non-dialysis opportunity reflects the loss of a multi-billion-dollar market with approximately 550K anemia patients that are not on dialysis.

Reduced Revenue EstimateThe FY25E revenue estimate for Vafseo was reduced by approximately 13% due to weaker than expected performance.

Akebia Therapeutics News

Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension

The major averages were higher near noon after the U.S. Senate voted on a spending package that would...

10d ago

CNC

Akebia reports Q3 EPS 0c vs (10c) last year

Reports Q3 revenue $58.766M, consensus $56.42M. “Through the quarter we’ve continued to make progress against our goal to...

10d ago

AKBA

Akebia price target lowered to $6 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Akebia (AKBA) to $6 from $8 and keeps a Buy...

21d ago

AKBA

Akebia says not in alignment with FDA on path forward for VALOR clinical trial

Akebia (AKBA) announced that after meeting with the FDA it has not come to alignment on a path...

22d ago

AKBA

Akebia Therapeutics Amends License Agreement with MEDICE

The latest update is out from Akebia Therapeutics ( ($AKBA) ). On November 12, 2025, Akebia Therapeutics and...

3d ago

AKBA

Akebia Therapeutics’ Earnings Call: Growth Amid Challenges

Akebia Therapeutics (($AKBA)) has held its Q3 earnings call. Read on for the main highlights of the call....

8d ago

AKBA

Akebia Therapeutics Reports Strong Q3 2025 Growth

Akebia Therapeutics ( ($AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia...

9d ago

AKBA

AKBA Upcoming Earnings Report: What to Expect?

Akebia Therapeutics (AKBA) is scheduled to report 3rd quarter earnings on 11/10/2025, before the market opens. Regarding Q3...

12d ago

AKBA

Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Akebia Therapeutics and decreased the price target...

21d ago

AKBA

Akebia Therapeutics Halts VALOR Trial for Vadadustat

Akebia Therapeutics ( ($AKBA) ) just unveiled an announcement. On October 28, 2025, Akebia Therapeutics announced that it...

22d ago

AKBA

Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Implications for Investors

Akebia Therapeutics (($AKBA)) announced an update on their ongoing clinical study. Akebia Therapeutics recently updated its clinical study...

24d ago

AKBA

Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications

Akebia Therapeutics (($AKBA)) announced an update on their ongoing clinical study. Akebia Therapeutics has initiated a study titled...

24d ago

AKBA

Akebia’s Vadadustat Study: A Potential Game-Changer in Anemia Treatment for CKD

Akebia Therapeutics (($AKBA)) announced an update on their ongoing clinical study. Study Overview: Akebia Therapeutics is conducting a...

2M ago

AKBA

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Akebia (AKBA) Therapeutics and Innovative Renal Care announced the broad availability of Vafseo for the treatment of anemia...

3M ago

AKBA

AKBA FAQ

What was Akebia Therapeutics’s price range in the past 12 months?

Akebia Therapeutics lowest stock price was $1.52 and its highest was $4.08 in the past 12 months.

What is Akebia Therapeutics’s market cap?

Akebia Therapeutics’s market cap is $467.04M.

When is Akebia Therapeutics’s upcoming earnings report date?

Akebia Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 112 days.

How were Akebia Therapeutics’s earnings last quarter?

Akebia Therapeutics released its earnings results on Nov 10, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.011 by $0.011.

Is Akebia Therapeutics overvalued?

According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akebia Therapeutics pay dividends?

Akebia Therapeutics does not currently pay dividends.

What is Akebia Therapeutics’s EPS estimate?

Akebia Therapeutics’s EPS estimate is >-0.01.

How many shares outstanding does Akebia Therapeutics have?

Akebia Therapeutics has 265,366,000 shares outstanding.

What happened to Akebia Therapeutics’s price movement after its last earnings report?

Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.011. Following the earnings report the stock price went down -18.137%.

Which hedge fund is a major shareholder of Akebia Therapeutics?

Currently, no hedge funds are holding shares in AKBA

Akebia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

75.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics (AKBA) Earnings & Revenues

Historic Earnings Reports

AKBA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a mix of strong prescription growth and financial improvements, offset by operational and adherence challenges impacting Vafseo's rollout. While revenue and patient access have grown significantly, the company faces hurdles in addressing logistics and adherence issues to sustain this growth.View all AKBA earnings summaries

AKBA Stock 12 Month Forecast

Average Price Target

$6.00

▲(277.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.5784615384615384,2.9469230769230768,3.315384615384615,3.6838461538461535,4.052307692307692,4.420769230769231,4.78923076923077,5.157692307692308,5.526153846153846,5.894615384615385,6.263076923076923,6.631538461538462,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.5015384615384617,2.793076923076923,3.0846153846153843,3.376153846153846,3.667692307692308,3.959230769230769,4.25076923076923,4.542307692307692,4.833846153846154,5.125384615384615,5.4169230769230765,5.708461538461538,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.21,2.4246153846153846,2.6392307692307693,2.853846153846154,3.0684615384615386,3.283076923076923,3.497692307692308,3.712307692307692,3.926923076923077,4.141538461538461,4.3561538461538465,4.570769230769231,4.785384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.28,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >